Source comparison
Tesamorelin + Ipamorelin Blend Fat Loss Results: Protocol Comparison
Tesamorelin monotherapy 2mg Evening, fasted 12–15% 3–5% Moderate: injection site reactions, transient hyperglycemia in 15–20% of users Ipamorelin monotherapy 300mcg 4–6% 2–3% Mild: occasional drowsiness, rare GI discomfort Tesamorelin + Ipamorelin blend 1mg +
This comparison does not assign a generated winner or score.
- Tesamorelin monotherapy
- 2mg
- Evening, fasted
- 12–15%
- 3–5%
- Moderate: injection site reactions, transient hyperglycemia in 15–20% of users
- Ipamorelin monotherapy
- 300mcg
- 4–6%
- 2–3%
- Mild: occasional drowsiness, rare GI discomfort
- Tesamorelin + Ipamorelin blend
- 1mg + 200–300mcg
- 15–18%
- 5–8%
- Moderate: similar to tesamorelin alone but lower incidence of hyperglycemia due to lower tesamorelin dose
- Exogenous GH (2–4 IU/day)
- N/A
- Morning + evening split
- 10–12%
- 6–9%
- High: edema, carpal tunnel syndrome, insulin resistance, costly
- The tesamorelin + ipamorelin blend delivers superior VAT reduction compared to either peptide alone because the dual-receptor activation pattern produces higher peak GH without requiring the high tesamorelin doses (2mg+) that increase hyperglycemia risk. Exogenous GH achieves similar subcutaneous fat loss but at much higher cost and side effect burden. And it suppresses endogenous GH production, creating dependency. The blend preserves natural pulsatile GH secretion while amplifying it.